Avadel Pharmaceuticals PLC AVDL.OQ AVDL.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Dublin-based company is expected to report a 48.2% increase in revenue to $61.498 million from $41.5 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.The company's guidance on May 7 2025, for the period ended June 30, was for revenue between $60.00 million and $63.00 million.
LSEG's mean analyst estimate for Avadel Pharmaceuticals PLC is for earnings of 3 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is $16.50, about 31.8% above its last closing price of $11.26
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.08 | -0.07 | -0.05 | Beat | 29.8 |
Dec. 31 2025 | -0.04 | -0.04 | -0.05 | Missed | -22.5 |
Sep. 30 2024 | -0.06 | -0.06 | -0.03 | Beat | 45.7 |
Jun. 30 2024 | -0.17 | -0.16 | -0.14 | Beat | 10 |
Mar. 31 2024 | -0.20 | -0.21 | -0.30 | Missed | -44.4 |
Dec. 31 2023 | -0.23 | -0.26 | -0.29 | Missed | -11.8 |
Sep. 30 2023 | -0.38 | -0.37 | -0.41 | Missed | -10.1 |
Jun. 30 2023 | -0.38 | -0.38 | -0.83 | Missed | -116 |
This summary was machine generated August 5 at 14:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)